Multiply Labs raised $75 million to scale robotic drug manufacturing for cell therapies. The company builds robotics systems meant to run steps between existing cell-therapy manufacturing instruments, including moving bags, sampling, and transferring material, while customers operate the underlying equipment. Multiply said published studies show robotic performance comparable to manual work on selected tasks and biological measures, but positioned the remaining manufacturing challenge as connecting discrete robotic tasks into full, reliable protocols in routine production. The company reported a 74% reduction in cost per dose and up to 100x more throughput, though it noted that some efficiency metrics depend on cleanroom production density rather than faster cell growth.